Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development programme as we advance to phase III trials. CT-388 is an important asset for unlocking the promise of our obesity pipeline, according to Roche, who added that the treatment is considered as a combination asset for petrelintide, an amylin analogue
Strategies for reducing cardiovascular risk are reviewed in the Atherosclerosis and Cardiovascular Disease protocol
To deliver 50mcg at 333mcg/mL, draw 0.15mL (15 units) instead of 0.1mL (10 units)
Histological techniques and immunohistochemistry For histological processing, liver and spleen tissues were fixed in phosphate buffer containing 10% formaldehyde and decalcified with EDTA
US$ 25.00
US$ 28.58
US$ 20.94
